The case for a new national program for the development of cancer therapeutics

Journal of Clinical Oncology

Volumn 19, Issue 12, 2001, Pages 3142-3153

  Schein, P S ^a  

^a United States Branch   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER RESEARCH; CANCER THERAPY; HEALTH CARE SYSTEM; HEALTH PROGRAM; PRIORITY JOURNAL;

EID: 0035876408     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.12.3142     Document Type: Article

References (23)

1. Clinical development of platinum complexes in therapy: A historical perspective and an update
2. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode
3. History and chemistry
4. Promotion of microtuble assembly in vitro by Taxol
5. Promising new agents under development by the Division of Cancer Treatments Diagnosis, and Centers of the National Cancer Institute
6. An information-intensive approach to the molecular pharmacology of cancer
7. The NCI anticancer drug screen: A smart screen to identify effectors of novel targets
8. Tyrosine-kinase inhibition in treatment of chronic myeloid leukemia
9. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey and man
10. The evaluation of anticancer drugs in man
11. Preclinical toxicology of anticancer agents
12. Qualitative prediction of drug toxicity in humans from toxicology in small and large animals
13. Clinical toxicity: Could it have been predicted? Pre-marketing experience
14. Clinical toxicity: Could it have been predicted? Post-marketing experience
15. Revisions of general guidelines for the preclinical toxicology of new cytotoxic anticancer agents in Europe
16. FDA's handling of UFT raises questions about the agency's isolation and grasp of science